New Classification Criteria Developed for Gout

This article originally appeared here.
Share this content:
New Classification Criteria Developed for Gout
New Classification Criteria Developed for Gout

WEDNESDAY, Sept. 30, 2015 (HealthDay News) -- New classification criteria have been developed with high specificity and sensitivity for gout, according to an article published in the October issue of Arthritis & Rheumatology.

Tuhina Neogi, M.D., Ph.D., from the Boston University School of Medicine, and colleagues developed new classification criteria for gout. They conducted a systematic review of the literature on advanced imaging for gout, a diagnostic study with monosodium urate monohydrate (MSU) crystals as the gold standard, a ranking exercise of paper patient cases, and an exercise in multicriterion decision analysis. The classification criteria were tested in an independent data set.

The researchers reported that the entry criterion for the new classification criteria required the occurrence of one or more episodes of peripheral joint or bursal swelling, pain, or tenderness. The presence of MSU crystals in a symptomatic joint/bursa or in a tophus was considered to be sufficient for classification of a patient with gout, without need for further scoring. The new classification criteria included clinical, laboratory, and imaging domains. High sensitivity and specificity were seen for the criteria (92 and 89 percent, respectively).

"The new classification criteria, developed using a data-driven and decision analytic approach, have excellent performance characteristics and incorporate current state-of-the-art evidence regarding gout," the authors write.

Several authors disclosed financial ties to the pharmaceutical industry.

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

FDA Permits Marketing of Brain Stimulation Device for OCD

FDA Permits Marketing of Brain Stimulation Device for ...

FDA previously approved transcranial magnetic stimulation for major depression, certain migraines

Comments Open on End of NIH Review for Gene Therapy Studies

Comments Open on End of NIH Review for ...

NIH oversight panel no longer plans to review all applications for gene therapy experiments

U.S. Measles Outbreak Hits 107 Cases in 21 States, D.C.

U.S. Measles Outbreak Hits 107 Cases in 21 ...

Outbreak on track to exceed last year's; most of the people who got measles weren't vaccinated

is free, fast, and customized just for you!




Already a member?

Sign In Now »